Quoin Pharmaceuticals Ltd.
QNRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671502
In the last 90 days, Quoin Pharmaceuticals Ltd. insiders filed 4 open-market purchases and 0 sales; 19 institutions reported holding it in 13F filings for Q2 2026, worth $6.29M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $280.0K in total
- 4
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −2 vs. previous quarter
- 19
- 13F valueReported value at the end of Q2 2026
- $6.29M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding QNRX, Q2 2026
No superinvestor reported holding QNRX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Quoin Pharmaceuticals Ltd. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 (view filing)9:40 PM ET | Aug 31 | 1 day | Carter Denise P.Chief Operating Officer | PPurchaseADSs | +20.5K | $4.88 | +$100.0K | +119.0%37.7K after | |
| Sep 1, 2026 (view filing)9:40 PM ET | Aug 31 | 1 day | Carter Denise P.Chief Operating Officer | PPurchaseADS | +10.2K | – | – | –10.2K after | Derivative |
| Sep 1, 2026 (view filing)9:39 PM ET | Aug 31 | 1 day | Myers MichaelChief Executive Officer | PPurchaseADSs | +20.5K | $4.88 | +$100.0K | +119.0%37.7K after | |
| Sep 1, 2026 (view filing)9:39 PM ET | Aug 31 | 1 day | Myers MichaelChief Executive Officer | PPurchaseADS | +10.2K | – | – | –10.2K after | Derivative |
| Sep 1, 2026 (view filing)9:39 PM ET | Aug 31 | 1 day | Lawlor Sally BridgetChief Financial Officer | PPurchaseADSs | +10.2K | $4.88 | +$50.0K | +2,328.2%10.7K after | |
| Sep 1, 2026 (view filing)9:39 PM ET | Aug 31 | 1 day | Lawlor Sally BridgetChief Financial Officer | PPurchaseADS | +5.12K | – | – | –5.12K after | Derivative |
| Sep 1, 2026 (view filing)9:38 PM ET | Aug 31 | 1 day | Culverwell Anthony JamesDirector | PPurchaseADSs | +6.15K | $4.88 | +$30.0K | +18.0%40.4K after | |
| Sep 1, 2026 (view filing)9:38 PM ET | Aug 31 | 1 day | Culverwell Anthony JamesDirector | PPurchaseADS | +3.07K | – | – | –3.07K after | Derivative |
| Oct 15, 2025 (view filing) | Oct 14 | 1 day | Langer DennisDirector | PPurchaseADSs | +15.2K | $8.49 | +$128.6K | +1,515,200.0%15.2K after | |
| Oct 15, 2025 (view filing) | Oct 14 | 1 day | Langer DennisDirector | PPurchaseADS | +60.6K | – | – | –15.2K after | Derivative4 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Quoin Pharmaceuticals Ltd. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Dauntless Investment Group, LLC | 214,987 | $1.04M | 1.80% | +18,395+9.4% | Added |
| Ikarian Capital, LLC | 211,538 | $1.02M | 0.17% | 00.0% | Unchanged |
| Stonepine Capital Management, LLC | 199,486 | $965.5K | 0.74% | +146,026+273.2% | Added |
| Millennium Management LLC | 112,323 | $543.6K | 0.00% | +36,076+47.3% | Added |
| SummitTX Capital, L.P. | 100,300 | $485.5K | 0.01% | 00.0% | Unchanged |
| Woodline Partners LP | 76,446 | $370.0K | 0.00% | −3,136−3.9% | Reduced |
| Standard Life Aberdeen plc | 75,000 | $363.0K | 0.00% | 00.0% | Unchanged |
| Soleus Capital Management, L.P. | 72,730 | $352.0K | 0.01% | 00.0% | Unchanged |
| AIGH Capital Management LLC | 70,000 | $338.8K | 0.03% | +19,000+37.3% | Added |
| Boothbay Fund Management, LLC | 59,838 | $289.6K | 0.01% | 00.0% | Unchanged |